Vasoactive intestinal peptide (VIP) is a peptide of 28 amino acid residues that belongs to the glucagon/secretin superfamily of peptides. It is produced in different regions of the nervous system, including the brain, trigeminovascular system and several autonomic nerves. Once released from neurons, it acts on vasoactive intestinal peptide receptor 1 (VPAC1), vasoactive intestinal peptide receptor 2 (VPAC2) and pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1), by mediating smooth muscle relaxation, vasodilation and water secretion. Along with other neuropeptides, such as calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP), it is released from the trigeminal afferents and exerts a strong vasodilating activity on the cranial vasculature, sharing the activation of adenylate cyclase. Especially, it shares 70% structure with PACAP and acts on the same receptors. But, unlike it, VIP cannot induce a long-lasting vasodilation and has a modest capability to induce migraine attacks. Whether a long-lasting infusion of VIP may induce a prolonged vasodilation in the cerebral vessels and migraine, as a twenty-minute infusion of PACAP, is unknown.

Start Date14 Jun 2019

Sponsor / Collaborator

Danish Headache Center

NCT00272896

/ CompletedNot ApplicableIIT

Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide (VIP) in Migraineurs

We hypothesized that infusion of VIP may induce headache/migraine in migraineurs and that VIP-induced headache may be associated with dilation of intra- and extracranial vessels. To test this hypothesis, we performed a double blind placebo-controlled crossover study in migraineurs and studied the effect on headache and cerebral and systemic hemodynamic parameters.

Start Date01 Oct 2004

Sponsor / Collaborator

Danish Headache Center

NCT00255320

/ CompletedNot ApplicableIIT

Experimental Headache Induced by Vasoactive Intestinal Polypeptide

We hypothesized that infusion of VIP may induce headache in healthy subjects and that VIP induced headache may be associated with dilatation of intra- and extracerebral blood vessels. To test this hypothesis, we performed a double blind placebo controlled crossover study in normal human volunteers and studied the effect on headache and cerebral as well as hemodynamic parameters.

Start Date01 Dec 2003

Sponsor / Collaborator

Danish Headache Center

100 Clinical Results associated with Vasoactive intestinal peptide(Danish Headache Center)

100 Translational Medicine associated with Vasoactive intestinal peptide(Danish Headache Center)

100 Patents (Medical) associated with Vasoactive intestinal peptide(Danish Headache Center)

1,227

Literatures (Medical) associated with Vasoactive intestinal peptide(Danish Headache Center)

15 Apr 2025·ACS Nano

Nanoparticle-Driven Tendon Repair: Role of Vasoactive Intestinal Peptide in Immune Modulation and Stem Cell Enhancement

Article

Author: Wang, Jinyu ; Zhang, Cheng ; Wang, Qianqian ; Dai, Guangchun ; Li, Gang ; Wang, Hao ; Shi, Liu ; Rui, Yunfeng ; Cao, Mumin ; Gao, Yucheng ; Sheng, Renwang ; Ai, Qi Yong H. ; Lu, Panpan

Tendon repair remains challenging owing to the limited capacity for endogenous repair. Vasoactive intestinal peptide (VIP) promotes bone tissue regeneration; however, its role in tendon repair remains unclear. In the present study, we demonstrated that VIP stimulated M2 polarization of macrophages and facilitated tendon regeneration by regulating immune homeostasis and maintaining the function of tendon stem/progenitor cells (TSPCs). Additionally, we established GelMa-loaded VIP@PLGA@ZIF-8 (VPZ) nanoparticles (VPZG) to enable the sustained and localized release of VIP at the site of patellar tendon injury in SD rats. The results of the in vitro experiments demonstrated that VPZG regulated the homeostasis of macrophage polarization by downregulating the NF-κB axis. VPZG also promoted efferocytosis and suppressed the release of proinflammatory factors. Additionally, VPZG enhanced the tenogenic differentiation of TSPCs when cocultured with macrophages. In vivo, we implanted VPZG at the site of patellar tendon injury, where it released VIP sustainably and slowly to promote tendon regeneration. This effect was achieved through the downregulation of the expression levels of various inflammatory factors, as well as the regulation of local immune homeostasis. In conclusion, our results demonstrated that VPZG facilitated tendon injury repair by regulating immune homeostasis and enhancing TSPC function. These findings suggest that VPZG is a promising avenue for the clinical improvement of tendon injury treatment.

01 Mar 2025·Journal of Investigative Dermatology

Vasoactive Intestinal Peptide Operates as a Negative Regulator of Human Hair Follicle Pigmentation Ex Vivo

Article

Author: Kassir, Ramtin ; Chéret, Jérémy ; Bedogni, Barbara ; Bertolini, Marta ; Gomez, Tatiana Gomez ; Paus, Ralf

A review.Human scalp hair follicles (HFs) are also known to produce numerous neuromediators themselves, primarily within the HF epithelium, whose functions in human HF physiol. remain incompletely understood.One important neuromediator that remains to be investigated in the context of HF melanocyte functions is the predominantly immunoinhibitory neuropeptide, vasoactive intestinal peptide (VIP).Therefore, we have asked in this pilot study whether and how VIP regulates human scalp HF pigmentation ex vivo, using our well-established organ culture assay for HF pigmentary research.In this denervated assay system, the native microenvironment of HF melanocytes remains intact and functional, whereas confounding impacts from VIP-secreting perifollicular nerves are eliminated.This showed that gp100+ melanocytes of the HFPU indeed prominently coexpress VPAC2 thus rendering them susceptible to direct stimulation by VIP.Interestingly, 1 mM VIP also significantly reduced the number of gp100+ and gp100+/microphthalmia-associated transcription factorepos. cells as well as overall gp100 immunoreactivity in the entire hair bulb of anagen VI HFs suggesting that VIP operates as a neg. regulator of the human HF melanocyte pool.Thus, VIP may reduce the local differentiation of HF melanocyte progenitors into mature, melanogenically active, gp100+/microphthalmia-associated transcription factor pos. HFPU melanocytes rather than primarily regulating their survival/activation.In summary, our pilot study directly in the human target organ unexpectedly reveals VIP as a neg. regulator of human HF pigmentation directly in the human target organ.VIP likely exerts its effects at the post-DCT level of melanogenesis, namely, by inhibiting tyrosinase activity and the formation of gp100+ premelanosomes.Higher concentrations of VIP may even reduce the number of HF melanocytes by inhibiting melanocyte differentiation from resident intrafollicular progenitors.

01 Feb 2025·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Vasoactive intestinal peptide induces metabolic rewiring of human-derived cytotrophoblast cells to promote cell migration

Article

Author: Vota, Daiana ; Rios, Daiana ; Paparini, Daniel ; Pérez Leirós, Claudia ; Merech, Fátima ; Hauk, Vanesa ; Lara, Brenda ; Ramhorst, Rosanna

The placenta has an extraordinary metabolic rate with high oxygen consumption. Extravillous cytotrophoblast cells (EVT) metabolism and function are critical to sustain their invasive phenotype supporting fetal development. Deficient EVT function underlies pregnancy complications as preeclampsia (PE) and fetal growth restriction (FGR). The vasoactive intestinal peptide (VIP) promotes human cytotrophoblast cell migration and invasion through mTOR signaling pathways suggesting its crucial role during placentation. Here we explored fatty acid uptake as well as lipid and glucose metabolism in human-derived cytotrophoblast cell function upon VIP stimulation. We found that VIP induced long chain fatty acid (LCFAs) uptake along with the expression of FATP2 transporter, CPT1 fatty acid oxidation (FAO)-rate limiting step importer, and lipid droplet accumulation. VIP induced the expression of glucose 6-P-dehydrogenase, a rate-limiting enzyme of the pentose phosphate pathway (PPP) and pyruvate dehydrogenase complex enzyme DLAT E2, without altering lactate secretion. This metabolic rewiring of trophoblast cells induced by VIP takes place without compromising mitochondrial function or reactive oxygen species (ROS) production. Moreover, cytotrophoblast cell migration induced by VIP required the three glycolysis, oxidative phosphorylation (OXPHOS) and FAO pathways. Our results provide evidence supporting VIP as a metabolic regulatory peptide in cytotrophoblast cells sustaining proper placentation and fetal growth.

100 Deals associated with Vasoactive intestinal peptide(Danish Headache Center)

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2012	Not Applicable	Myopia vasoactive intestinal peptide (VIP)	-	Vasoactive Intestinal Peptide (Control group)	dbkmfllqte(pkplfdeyty) = jhamdnehcx klgerrvrwf (utwujxykum ) View more	-	01 Mar 2012
				Saline injection	dbkmfllqte(pkplfdeyty) = zpjbxvhjcw klgerrvrwf (utwujxykum ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Vasoactive intestinal peptide(Danish Headache Center)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation